Alfuzosin

Introduction Overview

Generic Name

alfuzosin

Brand Name

Uroxatral

Dosage Form

Extended-release oral tablet

Drug Class

Alpha blockers (alpha-adrenergic receptor antagonists)

Pharmacokinetics

Absorption:

Alfuzosin is rapidly and extensively absorbed after oral administration, exhibiting a high bioavailability due to minimal first-pass metabolism. The drug is formulated as an extended-release tablet to provide consistent plasma concentrations over a 24-hour dosing interval. Peak plasma concentrations are typically achieved 8 to 12 hours after administration, reflecting the controlled-release nature of the formulation. The presence of food increases the extent and rate of absorption, which is why alfuzosin is recommended to be taken immediately after the same meal each day to optimize therapeutic effects and reduce variability in drug exposure.

Distribution:

Alfuzosin exhibits moderate plasma protein binding, primarily to alpha-1 acid glycoprotein. The drug distributes widely into tissues, including the prostate gland and lower urinary tract, which are the target sites for therapeutic action. The volume of distribution is sufficiently large, facilitating effective concentrations at the site of action. Although it crosses the blood-brain barrier minimally, CNS-related adverse events are uncommon but possible. Distribution kinetics enable alfuzosin to maintain effective receptor blockade in smooth muscle tissues of the bladder neck and prostate.

Metabolism:

Alfuzosin undergoes extensive hepatic metabolism via the cytochrome P450 enzyme system, predominantly through CYP3A4 isoenzymes. The metabolism results in various inactive metabolites with little or no pharmacological activity. Hepatic clearance is an essential route of metabolism, which necessitates caution or avoidance in patients with moderate to severe hepatic impairment due to the risk of drug accumulation and increased adverse effects. The metabolic pathway also contributes to potential drug-drug interactions, especially with CYP3A4 inhibitors such as certain antifungal agents, macrolide antibiotics, and protease inhibitors.

Elimination:

The elimination half-life of alfuzosin ranges from approximately 10 hours to 15 hours, supporting once-daily dosing. The drug and its metabolites are primarily excreted via the feces (through biliary elimination) and to a lesser extent in the urine. Renal excretion of unchanged alfuzosin is minimal, making dose adjustments less critical in mild-to-moderate renal impairment. Steady-state plasma concentrations are typically achieved within 2 to 3 days of once-daily dosing. The elimination profile ensures sustained receptor blockade with minimal plasma fluctuations.

Dosage Forms

Available Dosage Forms:

- Extended-release oral tablets: 10 mg

Dosages for Adults and Adolescents:

- The recommended dose for benign prostatic hyperplasia (BPH) is 10 mg orally once daily.
- The tablet should be taken immediately after the same meal each day to ensure consistent absorption.
- The extended-release formulation should be swallowed whole and should not be crushed, chewed, or broken.

Specific Patient Populations:

- Alfuzosin is not approved for use in pediatric patients under 18 years of age.
- Use in patients with moderate to severe hepatic impairment is contraindicated due to risk of accumulation.
- No specific dose adjustment is generally required for patients with mild to moderate renal impairment.
- Alfuzosin is not indicated for use in women; effects in pregnancy and breastfeeding are unknown and use is not recommended.
- Caution is advised in elderly patients due to increased sensitivity to hypotensive effects.

Clinical Guidelines:

- Patients should be monitored for blood pressure regularly due to alfuzosin’s potential to cause hypotension and dizziness.
- The timing of dose administration should be consistent daily to maintain therapeutic plasma concentrations.
- Adjustment or discontinuation may be necessary if adverse outcomes such as syncope or significant hypotension occur.

Mechanism Of Action

Alfuzosin is a selective antagonist of postsynaptic alpha-1 adrenergic receptors located in the smooth muscle of the prostate, bladder neck, and urethra. By selectively blocking these receptors, alfuzosin inhibits the catecholamine-induced contraction of these muscles, resulting in relaxation and decreased urethral resistance. This pharmacological effect improves urinary outflow in men suffering from benign prostatic hyperplasia (BPH), thereby alleviating lower urinary tract symptoms (LUTS) commonly associated with the condition.

At the molecular level, alfuzosin competitively binds to alpha-1 adrenergic receptor subtypes, particularly alpha-1A receptors predominant in prostatic smooth muscle, though it exhibits non-subtype-selective blockade. This receptor blockade prevents the activation of phospholipase C and the subsequent release of inositol triphosphate (IP3), which normally mobilizes intracellular calcium stores leading to smooth muscle contraction. The net biochemical outcome is reduced intracellular calcium concentrations, resulting in smooth muscle relaxation.

Clinically, the relaxation of smooth muscle in the prostate and bladder neck reduces bladder outlet obstruction, facilitating improved urine flow rates and reduced symptoms such as hesitancy, weak stream, and incomplete bladder emptying. Unlike agents that reduce prostate size, alfuzosin acts dynamically through muscle tone modulation, which allows for rapid improvement in symptoms.

Comparative analysis with other alpha blockers, such as tamsulosin and doxazosin, indicates that alfuzosin's pharmacodynamic profile confers effective symptom relief with a potentially lower incidence of cardiac-related adverse effects due to its limited effect on vascular alpha-1B receptors. Multiple clinical trials support its efficacy and tolerability in men with BPH, establishing alfuzosin as a valuable therapeutic option in the management of this condition.

Pharmacological Actions

Selective antagonism of postsynaptic alpha-1 adrenergic receptors in prostatic and bladder neck smooth muscle.
Relaxation of smooth muscle in lower urinary tract, decreasing urinary outflow resistance.
Reduction of lower urinary tract symptoms in men with benign prostatic hyperplasia.
Minimal impact on systemic vascular alpha-1 receptors, resulting in a lower risk of orthostatic hypotension compared to non-selective alpha-blockers.
Improvement of urinary flow rate and reduction of residual urine volume without altering prostate size.
Extended-release formulation provides stable plasma concentrations over 24 hours.
Metabolized via hepatic CYP3A4 enzymes, allowing interactions with drugs affecting this pathway.
Exerts a mild blood pressure-lowering effect, necessitating monitoring in patients with concomitant antihypertensive therapy.
Does not affect serum prostate-specific antigen (PSA) levels, allowing its use alongside PSA screening.
Negligible central nervous system penetration reduces risk of CNS-related side effects.

Therapeutic Or Clinical Uses

Management of benign prostatic hyperplasia (BPH) symptoms in adult men.
Improvement of urinary flow rate and relief of lower urinary tract symptoms (LUTS) associated with enlarged prostate.
Reduction of bladder outlet obstruction due to prostate smooth muscle relaxation.
Adjunctive therapy in patients where surgery is contraindicated or deferred.
Treatment of voiding difficulties related to BPH to enhance quality of life.
Off-label evaluation in some cases for chronic prostatitis symptoms relief through muscle relaxation.
Used when alpha-1 selective blockade is preferred to minimize cardiovascular adverse effects.
Potential alternative to other alpha blockers like tamsulosin in patients intolerant to those agents.

Side Or Adverse Effects

Dizziness, particularly postural or orthostatic hypotension, especially upon initiation.
Headache, ranging from mild to moderate severity.
Fatigue or general feeling of tiredness.
Rare episodes of syncope or fainting due to hypotension.
Cardiovascular effects such as palpitations have been reported infrequently.
Gastrointestinal disturbances including nausea in some patients.
Potential for allergic reactions including rash, urticaria, and rare angioedema.
Ejaculatory dysfunction or sexual side effects reported in some cases.
Upper abdominal pain and dyspepsia occasionally observed.
Risk of intraoperative floppy iris syndrome during cataract surgery; patients should inform their surgeon.
Rare reports of prolonged painful penile erection (priapism) requiring urgent medical attention.
Transient nasal congestion due to vasodilatory effects.
Occasional reports of dizziness when standing up abruptly leading to falls particularly in elderly patients.

Precautions

Use cautiously in patients with a history of hypotension or orthostatic hypotension.
Monitor blood pressure regularly due to potential for clinically significant hypotension.
Avoid sudden position changes to prevent dizziness and falls.
Inform patients about the risk of dizziness and recommend avoiding hazardous activities until response is known.
Caution in patients with hepatic impairment; alfuzosin is contraindicated in moderate to severe liver disease.
Not indicated or studied in women; avoid use during pregnancy and breastfeeding due to unknown risks.
Warn patients regarding potential interactions with other blood pressure lowering agents and nitrates.
Patients undergoing cataract surgery should notify their ophthalmologist about alfuzosin use to prevent intraoperative floppy iris syndrome.
Advise patients to avoid alcohol which may exacerbate hypotensive effects.
Ensure renal and liver function assessment prior to and during therapy, especially in elderly and comorbid patients.
Evaluate prostate specific antigen (PSA) levels before starting treatment to rule out prostate cancer.
Patients with a history of long QT syndrome should be monitored carefully due to limited data.
Advise reporting of any persistent or severe side effects such as fainting, chest pain or priapism immediately.
Do not discontinue therapy abruptly without medical advice.

Warnings

Contraindicated in patients with moderate to severe hepatic impairment.
May cause symptomatic hypotension and syncope, particularly at treatment initiation or dose escalation.
Risk of dizziness and fainting; patients should avoid driving or operating machinery until tolerability is established.
Potential for intraoperative floppy iris syndrome during cataract surgery; inform eye surgeons if patient is taking or has taken alfuzosin.
Concomitant use with other alpha blockers or vasodilators can potentiate hypotensive effects.
Use with caution in patients on antihypertensive medications, nitrates, or phosphodiesterase inhibitors to prevent severe hypotension.
Not indicated in pediatric patients under 18 years; safety and efficacy not established.
Potential allergic reactions—including anaphylaxis—require immediate medical attention.
Alcohol consumption should be limited due to the additive effect on blood pressure lowering and sedation.
May exacerbate symptoms of prostate cancer; prostate cancer should be ruled out prior to treatment initiation.

Contraindication

Known hypersensitivity or allergy to alfuzosin or any component of the formulation.
Moderate to severe hepatic impairment or liver disease.
Pregnancy and breastfeeding due to unknown safety profile.
Concurrent use with other alpha-adrenergic blockers for the treatment of hypertension or other indications.
Patients with severe hypotension or syncope history.
Use in pediatric population (under 18 years) is not recommended and contraindicated due to lack of data.

Drug Interactions

CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, erythromycin) increase alfuzosin plasma concentrations and risk of hypotension.
Concomitant use with other alpha-blockers (doxazosin, tamsulosin, prazosin, terazosin, silodosin) may increase risk of additive hypotensive effects.
Antihypertensive medications may produce excessive blood pressure lowering when combined with alfuzosin.
Nitrate medications (e.g., nitroglycerin) potentiate hypotensive risk and should be coadministered with caution or avoided.
Phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil) may cause additive vasodilation and hypotension.
Certain antiviral medications used for hepatitis C and HIV/AIDS may affect alfuzosin metabolism and plasma levels.
Antibiotics such as macrolides may inhibit CYP3A4 and elevate alfuzosin levels.
Antifungal agents like ketoconazole may increase alfuzosin exposure.
Concomitant use with medications that prolong QT interval should be monitored due to limited data.
Alcohol may enhance the hypotensive and sedative effects of alfuzosin.
Drugs that cause dehydration or electrolyte disturbances (e.g., diuretics) may increase risk of orthostatic hypotension when combined with alfuzosin.

Preparations Of The Drug

Uroxatral extended-release tablets 10 mg for oral administration.
Formulated as a once-daily extended-release tablet to maintain steady plasma concentrations.
Packaged in blister packs or bottles depending on manufacturer and country of distribution.
Tablets are film-coated to avoid irritation and facilitate swallowing; do not crush or chew.
Available in branded form 'Uroxatral' and also as generic alfuzosin extended-release tablets.
Prescribed with instructions to take immediately after the same meal daily to optimize absorption.
Typically supplied in quantities for 30-day treatment courses.
Storage recommended at room temperature, away from moisture, heat and light.
Available through prescription only.
Included in comparative treatment guidelines for BPH as a preferred alpha-1 blocker for lower urinary tract symptoms.